Edwards Lifesciences Corporation
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $2.94B | $3.05B | $1.13B | $769.0M | $862.8M | $1.18B | $1.18B | $714.1M |
| Accounts Receivable | $659.6M | $609.1M | $771.5M | $643.0M | $582.2M | $514.6M | $543.6M | $456.9M |
| Inventory | $1.13B | $1.09B | $903.5M | $875.5M | $726.7M | $802.3M | $640.9M | $607.0M |
| Total Current Assets | $6.74B | $6.29B | $4.04B | $3.10B | $3.18B | $3.09B | $2.98B | $2.29B |
| Property, Plant & Equipment | $1.81B | $1.69B | $1.59B | $1.63B | $1.55B | $1.40B | $1.06B | $867.5M |
| Goodwill | $1.77B | $1.78B | $1.15B | $1.06B | $1.17B | $1.17B | $1.17B | $1.11B |
| Intangible Assets (Excl. Goodwill) | $1.13B | $1.18B | $399.4M | $285.2M | $323.6M | $331.4M | $336.5M | $343.2M |
| Total Assets | $13.70B | $13.06B | $9.36B | $8.29B | $8.50B | $7.24B | $6.49B | $5.32B |
| Liabilities | ||||||||
| Accounts Payable | $227.5M | $197.4M | $186.6M | $201.9M | $204.5M | $196.5M | $180.4M | $134.0M |
| Total Current Liabilities | $1.81B | $1.51B | $1.20B | $1.02B | $1.03B | $893.9M | $902.4M | $876.6M |
| Long-Term Debt | $598.3M | $597.7M | $597.0M | $596.3M | $595.7M | $595.0M | $594.4M | $593.8M |
| Total Liabilities | $3.36B | $2.99B | $2.64B | $2.49B | $2.67B | $2.66B | $2.34B | $2.18B |
| Stockholders' Equity | ||||||||
| Retained Earnings | $14.24B | $13.17B | $8.99B | $7.59B | $6.07B | $4.57B | $3.74B | $2.69B |
| Total Stockholders' Equity | $10.34B | $10.00B | $6.65B | $5.81B | $5.84B | $4.57B | $4.15B | $3.14B |